Semaglutide was the most cost-effective treatment compared to exenatide, dulaglutide, liraglutide, or no treatment in short-term analyses (approximately one and a half years) that assessed quality-adjusted life years and incremental cost-effectiveness ratios [135,136,137,138,139,140,141,142,143,144]
Existing scars may flatten or soften, particularly newer scars (less than 2 years old)
In a phase 1b study of co-administered SC semaglutide 2.4 mg with cagrilintide 0.164.5 mg (CagriSema) in participants with overweight or obesity, cagrilintide exposure was proportional to dose and did not affect semaglutide exposure or elimination [7]
Stem Cells 34 , 28402851 (2016)
This line of inquiry has been extended to compound-resistant cases, with speculation that immune modulation may underlie observed differences